Related Experiment Videos
Polycythemia vera responds to imatinib mesylate
C Michael Jones1, Tina Marie Dickinson
1jonesmd@bellsouth.net
The American Journal of the Medical Sciences
|March 18, 2003
Summary
Two polycythemia vera patients negative for JAK2 V617F mutation responded well to imatinib mesylate. This targeted therapy offers an alternative for patients intolerant to standard treatments like hydroxyurea or interferon.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Polycythemia vera is a myeloproliferative neoplasm characterized by increased red blood cell production.
- Standard treatments include hydroxyurea and interferon-alpha, but some patients are intolerant or resistant.
- The JAK2 V617F mutation is common in polycythemia vera, but a subset of patients are mutation-negative.
Observation:
- Two patients with polycythemia vera were identified as JAK2 V617F-negative.
- These patients experienced intolerance to both hydroxyurea and interferon-alpha.
- Clinical assessment revealed excellent responses to imatinib mesylate (STI-571) in both individuals.
Findings:
- Imatinib mesylate demonstrated significant clinical efficacy in JAK2 V617F-negative polycythemia vera patients.
- The positive response suggests a potential role for c-kit signaling pathways in this patient subset.
- This finding aligns with imatinib's known inhibitory effect on c-kit tyrosine kinase activity.
Implications:
- Imatinib mesylate represents a promising therapeutic option for polycythemia vera patients with specific genetic profiles and treatment limitations.
- Further research into the role of c-kit and other tyrosine kinases in polycythemia vera is warranted.
- Personalized treatment strategies may improve outcomes for patients with myeloproliferative neoplasms.